Dare to be the next global leader of R&D in Pharma.
‘After becoming a global R&D center, our projects in China have grown 50% annually. Syncing up with the global pipeline, key projects have achieved 100% growth, with early-stage R&D projects accounting for 20%. AstraZeneca R&D China has shifted focus to earlier-stage research compared to the more traditional confirmatory studies and new drug launches. We are now leading in certain high-prevalence disease areas in China.’ A summary of the recent developments by Dr. He Jing, Global Senior VP & President of R&D China.
As a crucial member of AstraZeneca’s Global R&D Network, continuously working with the philosophy of ‘In China, with China, for Global’ to enhance local R&D capabilities. Currently, the R&D China team consists of more than 900 people, covering oncology, respiratory & immunology, vaccines & immune therapies, cardiovascular, renal & metabolism, as well as rare diseases. With over 180 projects in our R&D pipeline, covering the entire clinical development process ranging from translational medicine to Phase III clinical trials.
AstraZeneca, recognized as a 'China Outstanding Employer' for 14 years, supports talent's self-worth. At R&D China, we push for the unconventional, foster creativity, and inspire motivation. Your personal growth and development will help us realize our common vision.
